| program | Indication | Country | Discovery | Pre-clinical | Phase I | Phase II | Phase III | BLA |
|---|---|---|---|---|---|---|---|---|
| LP-003 (new generation of anti-IgE antibody) | Allergic rhinitis (AR) |  |
|
|||||
| Chronic spontaneity urticaria (CSU) | |
|
||||||
| Asthma | |
|
||||||
| Food allergy | |
|
||||||
| Asthma COPD overlapped (ACO) | - |
|
| program | Indication | Country | Discovery | Pre-clinical | Phase I | Phase II | Phase III | BLA |
|---|---|---|---|---|---|---|---|---|
| LP-005 (C3 x C5 bi-functional antibody) | Paroxysmal nocturnal hemoglobinuria (PNH) | |
|
|||||
| IgA nephropathy (IgAN) | |
|
||||||
| Lupus nephropathy (LN) | |
|
||||||
| C3 glomerulopathy (C3G) | |
|
||||||
| amyotrophic lateral sclerosis (ALS) | - |
|
||||||
| Generalized myasthenia gravis (gMG) | - |
|
||||||
| Myelin-associated glycoprotein associated neuropathies (MAG-PN) | - |
|
| program | Indication | Country | Discovery | Pre-clinical | Phase I | Phase II | Phase III | BLA |
|---|---|---|---|---|---|---|---|---|
| LP-001 (long-acting EPO-Fc) | Myelodysplastic syndrome (MDS) | |
|
|||||
| Chronic kidney disease anemia (CKD Anemia) | |
|
||||||
| LP-002(long-acting growth hormone-Fc) Q2W-Q4W | Growth hormone deficiency (GHD) | - |
|
Source: Humbert M , Bousquet J , Bachert C ,et al.IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy[J].The Journal of Allergy and Clinical Immunology In Practice, 2019, 7(5).DOI:10.1016/j.jaip.2019.02.030.
Source: Gould H J , Bryan Y C .IgE repertoire and immunological memory: Compartmental regulation and antibody function[J].International Immunology, 2018(9):9.DOI:10.1093/intimm/dxy048.
| Items | LP-003 | Omalizumab | Ligelizumab |
|---|---|---|---|
| KD* Affinity to IgE | 2.08 pM | 1790 pM | 12.1 pM[a] |
| FcεRI bioassay | ++++ | ++ | +++ |
| FcεRI bioassay | ++++ | ++ | +++ |
| T 1/2 (healthy volunteers) | Q45~75 days | 17~20 days[b] | ~20 days[c] |
| FcεRI bioassay | ++++ | ++ | +++ |
| program | Indication | Country | Discovery | Pre-clinical | Phase I | Phase II | Phase III | BLA |
|---|---|---|---|---|---|---|---|---|
| LP-003 (new generation of anti-IgE antibody) | Allergic rhinitis (AR) | |
|
|||||
| Chronic spontaneity urticaria (CSU) | |
|
||||||
| Asthma | |
|
||||||
| Food allergy | |
|
||||||
| Asthma COPD overlapped (ACO) | - |
|
Source: Posch W , Bermejo-Jambrina M , Lass-Flrl C ,et al.Role of Complement Receptors (CRs) on DCs in Anti-HIV-1 Immunity[J].Frontiers in Immunology, 2020, 11.DOI:10.3389/fimmu.2020.572114..
Source: https://www.theisn.org/initiatives/toolkits/complement-mediated-kidney-disease-toolkit/#Overview-Complement
| Items | LP-005 | Eculizumab | Ravulizumab | Pegcetacoplan APL-2 | KP-104 | MASP-2 OMS721 |
|---|---|---|---|---|---|---|
| Target C5 | Yes | Yes | Yes | N/A | Yes | N/A |
| Target C3 | Yes | N/A | N/A | Yes | Yes | N/A |
| CP bioassay | ++++ | +++ | +++ | ++ | +++ | N/A |
| CP bioassay | ++++ | +++ | +++ | ++ | +++ | N/A |
| CP bioassay | ++++ | +++ | +++ | ++ | +++ | N/A |
| program | Indication | Country | Discovery | Pre-clinical | Phase I | Phase II | Phase III | BLA |
|---|---|---|---|---|---|---|---|---|
| LP-005 (C3 x C5 bi-functional antibody) | Paroxysmal nocturnal hemoglobinuria (PNH) | |
|
|||||
| IgA nephropathy (IgAN) | |
|
||||||
| Lupus nephropathy (LN) | |
|
||||||
| C3 glomerulopathy (C3G) | |
|
||||||
| amyotrophic lateral sclerosis (ALS) | - |
|
||||||
| Generalized myasthenia gravis (gMG) | - |
|
||||||
| Myelin-associated glycoprotein associated neuropathies (MAG-PN) | - |
|
